Accumulation of amyloid beta (Aβ) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood–brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAβ40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.
|Original language||English (US)|
|Number of pages||9|
|Journal||Nanomedicine: Nanotechnology, Biology, and Medicine|
|State||Published - Feb 2019|
Bibliographical noteFunding Information:
Funding: This work was supported by the Minnesota Partnership for Biotechnology and Medical Genomics grant (KKK and JFP). A portion of this work was performed at the National High Magnetic Field Laboratory which was supported by the State of Florida and the National Science Foundation (DMR-1157490 and DMR-1644779). Further, National Science Foundation (NSF) is acknowledged for funding a portion of this work (SR 1735968).
© 2018 Elsevier Inc.
- Alzheimer's disease (AD)
- BBB permeating peptide
- Cerebrovascular amyloid
- Magnetic resonance imaging (MRI)
- Targeted nanoparticles